Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms [21] [20] GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations [18] [19] Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication [23] [24] Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations

Sometimes, doctors advise against using a GLP-1 if you are using medications for ADHD, hypertension, or another sort of mood disorder
Marsh J, Mukherjee P, Seyfried TN
Key findings included: 14 percent lower overall risk of developing any substance use disorder 18 percent lower risk of alcohol use disorder (hazard ratio HR 0.82) 14 percent lower risk of cannabis use disorder 20 percent lower risk of cocaine use disorder 20 percent lower risk of nicotine dependence 25 percent lower risk of opioid use disorder These included: 30 percent fewer substance-related emergency department visits 25 percent fewer hospitalizations 40 percent lower overdose risk 50 percent lower risk of drug-related death Possible Mechanism: Effects on Brain Reward Pathways GLP-1 receptor agonists mimic a hormone involved in regulating insulin secretion, appetite, and gastric emptying
doi:10.3389/frph.2021.792920 96